Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

The prognostic value of total T3 after acute cerebral infarction is age-dependent: a retrospective study on 768 patients

BMC Neurology201919:54

https://doi.org/10.1186/s12883-019-1264-z

  • Received: 17 November 2018
  • Accepted: 28 February 2019
  • Published:
Open Peer Review reports

Abstract

Background

Serum triiodothyronine (T3) concentration was reported to be associated with the prognosis after acute ischemic stroke. The aim of this study was to evaluate the effect of age on the prognostic value of thyroid-related hormones after an acute ischemic stroke.

Methods

This was a retrospective study involving the review of 1072 ischemic stroke patients who had been consecutively admitted to the hospital within 72 h of symptom onset. Total triiodothyronine (T3), total thyroxine (T4), free T3, free T4, and thyroid-stimulating hormone (TSH) were assessed to determine their values for predicting functional outcome at the first follow-up clinic visits, which usually occurred 2 to 4 weeks after discharge from the hospital.

Results

A total of 768 patients were finally included in the study and divided into two age groups: a younger group (age < 65 years) and an older group (age ≥ 65 years). On univariate analysis, four factors—lower total T3, free T3 concentrations, higher scores on the National Institute of Health Stroke Scale (NIHSS) and the presence of atrial fibrillation—were associated with poor functional outcomes in both groups. In addition, older age, female gender, higher free T4, and lower TSH levels were also associated with poor function in the older group. On multiple logistic regression analysis, higher NIHSS scores (odds ratio [OR] =1.95; 95% confidence interval [CI], 1.66–2.30; P ≤ .001) and lower total T3 concentrations (OR = 0.06; 95% CI, 0.01–0.68; P = .024) remained independently associated with poor functional outcome in the older group. However, the independent association with poor function of lower total T3 was not confirmed in the younger group.

Conclusions

The prognostic value of low total T3 is age-associated and more meaningful in an older population.

Keywords

  • Thyroid-related hormones
  • Ischemic stroke
  • Functional outcome

Background

Previous studies have shown an association of serum triiodothyronine (T3) concentration with prognosis after acute ischemic stroke; that is, a reduction in T3 level without an elevation in thyroid-stimulating hormone (TSH) (i.e., low T3 syndrome) was reported to be associated with poorer clinical outcomes [14]. Better survival after acute stroke was found in one study [1] even when the cut-off point used was the median T3 level, showing that a lower T3 level, even when within the normal range, may be associated with a poorer prognosis. Furthermore, our previous study confirmed that a lower total T3 concentration within the normal range was independently associated with a poorer short-term outcome after ischemic stroke [5].

As is well known, an individual’s levels of thyroid hormones change with age: serum total and free T3 levels are reported to decrease with age [6, 7], whereas serum total and free thyroxine (T4) levels remain unchanged [69] or increase [10]. It is further believed that these alterations create major difficulties in attempting to determine thyroid status in the elderly with precision [11]. As a special physiologic status, aging may also influence the prognostic value of some known or possible predictors of outcome after stroke; Therefore, this study was designed to investigate the effect of age on the prognostic value of thyroid-related hormones after acute ischemic stroke.

Methods

Study population

We reviewed all of the available charts of patients admitted with acute ischemic stroke at the acute stroke unit of the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, between January 2011 and December 2013. Included patients met the following criteria: (1) a diagnosis of acute ischemic stroke with a new focal neurologic deficit and a corresponding lesion on magnetic resonance imaging or delayed computed tomography; on admission, non-contrast head computed tomography scan was perfomed to exclude intracranial hemorrhage; (2) admission within 72 h after symptom onset; and (3) thyroid function testing within 24 h of admission. Patients with known thyroid disease, biochemically defined overt thyroid disease, or the use of medications that affect thyroid function were excluded. To avoid any confounding effects, subjects with cancer, hematologic diseases, severe renal or liver failure, and inflammatory or infectious diseases were also excluded. All patients received standard routine treatment and intravenous thrombolysis was considered for all patients presenting within 4.5 h of symptom onset.

Data collection

Baseline characteristics—including demographic data; stroke risk factors, such as a history of hypertension, smoking, diabetes mellitus, hyperlipidemia, transient ischemic attacks, coronary artery disease, and atrial fibrillation; laboratory parameters routinely measured in the emergency department, including routine blood count, admission glucose, and C-reactive protein (CRP) levels; and neurologic deficits—were recorded. Blood samples for CRP were taken at the time of admission and analyzed by an immunoturbidimetric method using the Abbott Architect c16000 Biochemistry Analyzer (Abbott Laboratories Inc., LakeBluff, IL, USA).

Thyroid function tests examined TSH, total T3, total T4, free T3, and free T4 levels. Serum concentrations of these hormones were measured using the Abbott i4000 Chemiluminescent Microparticle Immunoassay (Abbott Laboratories Inc., LakeBluff, IL, USA). Normal ranges of thyroid hormones are as follows: TSH, 0.35–4.94 IU/L; total T3, 0.57–1.59 ng/mL; total T4, 4.87–11.72 μg/dL; free T3, 1.71–3.71 pg/mL; and free T4, 0.7–1.48 ng/dL.

The severity of stroke on admission was assessed using the National Institutes of Health Stroke Scale (NIHSS). Stroke subtype was divided into 3 groups according to the vessels involved: anterior circulation group, posterior circulation group, and both anterior and posterior circulation group. Functional outcomes were evaluated using the modified Rankin Scale (mRS) at the first follow-up clinic visit, which usually occurred 2 to 4 weeks after discharge from the hospital. Patients were classified into 2 outcome groups: poor functional outcome (mRS > 2) and good functional outcome (mRS ≤2). All of the evaluations were performed by the study neurologists.

Data analysis

Data were analyzed using SPSS 22.0 software for Windows. Data are expressed as medians (interquartile range [IQR]) or mean ± standard deviation (SD) for quantitative variables and as numbers (percent) for qualitative variables. Pearson correlation was used to evaluate the association of age with thyroid hormone levels. The differences in thyroid-related hormones were evaluated with the division of data into two groups based on age (< 65 years for the younger group and ≥ 65 years for the older group) [12, 13]. Simultaneous comparisons of other parameters in the two age-based groups were performed. In addition, comparisons with clinical and laboratory variables between different outcome groups were determined in each group. Continuous data were compared by independent sample t tests and, for categorical variables, chi-square tests. Besides, spearman’s rank correlation was performed to assess the association between thyroid hormone levels and stroke severity on admission in each group. Then, the variables associated with significant differences between outcomes in each of the two groups were included in multiple logistic regression analysis and a backward likelihood ratio test was used to identify the independent predictors of poor functional outcome after stroke in each group. Receiver operating characteristics (ROC) curve analysis was used to assess discrimination and results are reported as area under the curve (AUC). All of the statistical tests were two-tailed, and P < .05 indicated statistical significance.

Results

During the study period, 1072 ischemic stroke patients were admitted to our acute stroke unit within 72 h after symptom onset. Of these, 768 patients were included in the finally analysis and 304 patients were excluded. The reasons for exclusion were as follows: previous thyroid disease (n = 19); biochemically defined overt or subclinical thyroid disease (n = 57), defined as any of the following thyroid function tests alteration at admission: abnormal TSH, abnormal free T4 or total T4, raised free T3 or total T3 (n = 68, low free T3 or total T3 with normal TSH was taken as a marker of low T3 syndrome and therefore not considered as a primary thyroid disorder [14]); cancer (n = 51); hematologic diseases (n = 13); severe renal or liver failure (n = 26); inflammatory or infectious diseases (n = 32); and no thyroid function test within 24 h of admission (n = 38).

The baseline characteristics of the included patients are summarized in Table 1. Both the younger and older groups had a male predominance, however, the proportion of males appeared to decrease with age (57.6% in older group versus 66.4% in younger group, P = .016). There was no significant difference in admission NIHSS (P = .703) and artery system involved between the two groups. Analysis of parameters related to patient history between the two groups showed that the older group included more patients with a history of previous cerebral infarction (P ≤ .001), atrial fibrillation (P ≤ .001), and hypertension (P = .001), while the younger group included more patients with a history of hyperlipidemia (P ≤ .001) and smoking (P ≤ .001). In addition, compared with the patients in the younger group, the subjects in the older group had higher levels of blood pressure on admission (P ≤ .001 for both systolic and diastolic blood pressure), with higher TSH (P = .002), free T4 (P = .011) and CRP levels (P = .001) and lower total T3 and free T3 concentrations (both P ≤ .001).
Table 1

Baseline characteristics of patients with acute ischemic stroke (grouped by age)

Variables

Younger Age Group (age < 65 yr)

(n = 327)

Older Age Group (age ≥ 65 yr)

(n = 441)

P Value

Age (years) (median, IQR)

57 (51–61)

76 (70–80)

≤.001

Sex (male, %)

217 (66.4%)

254 (57.6%)

.016

Smoking (n,%)

167 (51.1%)

148 (33.6%)

≤.001

Hyperlipidemia (n,%)

177 (54.1%)

128 (29.0%)

≤.001

Coronary artery disease (n,%)

21 (6.4%)

39 (8.8%)

.225

Diabetes mellitus (n, %)

84 (25.7%)

104 (23.6%)

.553

Atrial fibrillation (n, %)

16 (4.9%)

56 (12.7%)

≤.001

Previous stroke (n, %)

21 (6.4%)

69 (15.6%)

≤.001

Transient ischemic attacks (n, %)

9 (2.8%)

15 (3.4%)

.679

History of hypertension (n, %)

191 (58.4%)

311 (70.5%)

.001

Systolic blood pressure (mmHg) (median, IQR)

152 (132–170)

160 (142–175)

≤.001

Diastolic blood pressure (mmHg) (median, IQR)

85 (77–95)

80 (71–88)

≤.001

Baseline NIHSS scores (median, IQR)

2 (1–5)

2 (1–5)

.703

Anterior circulation group

229 (70.0%)

304 (68.9%)

.752

Posterior circulation group

91 (27.8%)

125 (28.3%)

.935

TSH (IU/L) (median, IQR)

1.52 (1.01–2.02)

1.67 (1.05–2.40)

.002

total T4(μg/dL) (median, IQR)

6.41 (5.58–7.27)

6.59 (5.82–7.50)

.066

total T3 (ng/mL) (median, IQR)

0.85 (0.72–0.98)

0.81 (0.69–0.92)

≤.001

free T4 (ng/dL) (median, IQR)

1.07 (0.99–1.17)

1.11 (1.00–1.21)

.011

free T3 (pg/mL) (median, IQR)

2.54 (2.29–2.89)

2.45 (2.16–2.74)

≤.001

Initial WBC count (× 109/L) (median, IQR)

7.20 (5.90–9.45)

6.80 (5.60–8.30)

.051

Glucose on admission (mmol/L) (median, IQR)

7.07 (5.82–9.59)

7.09 (5.82–9.46)

.471

C-reactive protein (mg/dL) (median, IQR)

1.40 (0.80–2.70)

2.40 (0.90–5.98)

.001

poor functional outcome (mRS > 2) (n, %)

38 (11.6%)

64 (14.5%)

.282

IQR interquartile range, NIHSS National Institutes of Health Stroke Scale, TSH thyroid-stimulating hormone, T4 thyroxine, T3 triiodothyronine, WBC white blood cell, mRS modified Rankin Scale

There were negative correlations between age and levels of total T3 (r = − 0.190, P ≤ .001) and free T3 (r = − 0.203, P ≤ .001) and positive correlations between age and levels of total T4 (r = 0.077, P = .032) and free T4 (r = 0.115, P = .001) but not TSH (P = .058).

There were negative correlations between NIHSS scores and levels of total T3 (r = − 0.159, P = 0.004 in the younger group; r = − 0.197, P = 0.000 in the older group) and free T3 (r = − 0.186, P = 0.001 in the younger group; r = − 0.232, P = 0.000 in the older group) in both the younger and older groups. Besides, there were positive correlations between NIHSS scores and levels of total T4 (r = 0.112, P = 0.042) in the younger group, while a negative correlation was found between NIHSS scores and TSH (r = − 0.095, P = 0.046) in the older group.

At the study’s end point, a total of 38 patients (11.6%) in the younger group had poor functional outcomes with no significant difference as compared with the older group (64 subjects, 14.5%, P = .282). As shown in Table 2, the variables associated with poor functional outcome on univariate analysis in the two groups were not the same. In the younger group, poor functional outcome on univariate analysis was associated with lower total T3 and free T3 concentrations, higher NIHSS scores and the presence of atrial fibrillation. In the older group, except the four items mentioned in the younger group, older age, female gender, higher free T4, and lower TSH levels were also associated with poor function on univariate analysis.
Table 2

Clinical and laboratory findings on admission according to outcome in the two age groups

Variables

Younger Group

(age < 65 yr)

P Value

Older Group

(age ≥ 65 yr)

P Value

Good functional outcome

(mRS ≤ 2) (n = 289)

Poor functional outcome (mRS > 2) (n = 38)

 

Good functional outcome

(mRS ≤2) (n = 377)

Poor functional outcome (mRS > 2) (n = 64)

 

Age (years)a

57 (51–61)

58 (52–62)

.169

75 (70–80)

78 (72–83)

.016

Sex (male, %)

191 (66.1%)

26 (68.4%)

.856

225 (59.7%)

29 (45.3%)

.040

Smoking (n,%)

142 (49.1%)

25 (65.8%)

.054

133 (35.3%)

15 (23.4%)

.064

Hyperlipidemia (n,%)

156 (54.0%)

21 (55.3%)

.881

105 (27.9%)

23 (40.0%)

.188

Coronary artery disease (n, %)

16 (5.5%)

5 (13.2%)

.081

33 (8.8%)

6 (9.4%)

.871

Diabetes mellitus (n, %)

75 (26.0%)

9 (23.7%)

.846

87 (23.1%)

17 (26.6%)

.633

Atrial fibrillation (n, %)

10 (3.5%)

6 (15.8%)

.006

41 (10.9%)

15 (23.4%)

.008

Previous stroke (n, %)

18 (6.2%)

3 (7.9%)

.722

56 (14.9%)

13 (20.3%)

.352

Transient ischemic attacks (n, %)

7 (2.4%)

2 (5.3%)

.281

13 (3.4%)

2 (3.1%)

.625

History of hypertension (n, %)

168 (58.1%)

23 (60.5%)

.862

270 (71.6%)

41 (64.1%)

.237

Systolic blood pressure (mm Hg)a

152 (131–170)

151 (135–165)

.525

161 (141–176)

158 (147–171)

.469

Diastolic blood pressure (mm Hg)a

85 (77–95)

83 (78–99)

.610

80 (71–88)

77 (67–87)

.276

Baseline NIHSS scoresa

2 (1–3)

11 (8–15)

≤.001

2 (1–4)

11 (8–14)

≤.001

TSH (IU/L)a

1.52 (1.01–2.05)

1.60 (1.14–1.96)

.951

1.73 (1.09–2.45)

1.36 (0.85–1.98)

.021

total T4 (μg/dL)a

6.37 (5.55–7.23)

6.88 (5.89–7.82)

.068

6.51 (5.79–7.47)

6.96 (6.03–7.95)

.051

total T3 (ng/mL)a

0.86 (0.73–0.98)

0.76 (0.63–0.92)

.013

0.82 (0.71–0.93)

0.71 (0.57–0.83)

≤.001

free T4 (ng/dL)a

1.07 (0.98–1.17)

1.11 (0.99–1.21)

.257

1.10 (1.00–1.20)

1.13 (1.03–1.29)

.040

free T3 (pg/mL)a

2.59 (2.31–2.93)

2.40 (2.01–2.66)

.001

2.49 (2.20–2.77)

2.21 (1.92–2.53)

≤.001

Initial WBC count (×109/L)a

7.10 (5.90–8.95)

8.60 (6.28–10.60)

.134

6.60 (5.60–8.30)

7.80 (6.30–8.40)

.175

Glucose on admission (mmol/L)a

7 (5.78–9.24)

8.19 (6.06–13.36)

.072

7.04 (5.81–9.36)

7.29 (5.85–10.72)

.516

C–reactive protein (mg/dL)a

1.40 (0.80–2.80)

1.7 (0.80–2.40)

.366

2.10 (0.90–5.90)

3.45 (1.25–8.13)

.876

IQR interquartile range, NIHSS National Institutes of Health Stroke Scale, TSH thyroid–stimulating hormone, T4 thyroxine, T3 triiodothyronine, WBC white blood cell, mRS modified Rankin Scale

aExpressed as median (IQR)

On multiple logistic regression analysis, only the NIHSS scores remained independently associated with poor functional outcome in the younger group (OR = 1.56; 95% CI 1.39–1.76; P ≤ .001). Neither total T3 nor free T3 was independently associated with a poor functional outcome in this group. However, in the older group, in addition to the NIHSS scores (OR = 1.95; 95% CI 1.66–2.30; P ≤ .001), lower total T3 (OR = 0.06; 95% CI 0.01–0.68; P = .024) was also confirmed to be independently associated with poor functional outcome, even though with a less AUC [0.66 (95% CI 0.59–0.74) than NIHSS [0.87(95% CI 0.85–0.88)]. This finding indicates that the prognostic value of a lower total T3 is age-associated and more meaningful in an older population.

Discussion

This study demonstrates that in euthyroid patients with acute ischemic stroke, the association of total T3 level with functional outcome differs with age. In patients at or above 65 years of age, a lower total T3 concentration was an independent predictor of poor functional outcome after ischemic stroke. However, none of the thyroid–related hormones, including total T3, were independently associated with a poor functional outcome in patients below 65 years of age.

Low T3 syndrome and lower T3 serum concentrations are common complications in acute cerebrovascular disease [15] and are reported to be associated with greater mortality and poorer clinical outcomes after ischemic stroke [14, 1517]. For example, it has been reported that ischemic stroke patients with low T3 syndrome were at increased risk for poor functional outcome at follow–up (scheduled from 2 to 4 weeks after ischemic stroke) [3]. In addition, better survival after acute stroke was found even when the cutoff was the median total T3 level [1]. Furthermore, our previous study showed that lower total T3 concentrations that were within the normal ranges were independently associated with poorer short-term outcomes after ischemic stroke [5]. Moreover, a meta-analysis conducted recently to evaluate the prognostic value of thyroid hormones in acute ischemic stroke confirmed the predictive value of lower T3 levels for a poor prognosis in acute ischemic stroke [18]. However, the present study shows that the prognostic value of lower total T3 for poor outcome after ischemic stroke may not be confirmed in patients of all ages. In those below age 65, neither total T3 nor free T3 concentrations were shown to be independently associated with functional outcome, suggesting that this association with outcome after cerebral infarction is age-dependent, having greater clinical significance in older patients. To the best of our knowledge, such an association has not been reported previously.

T3 has been shown to have neuroprotective effects in animal models. Several attempts have been made to directly investigate the neuroprotective actions of T3 in mice models of transient middle cerebral artery occlusion [1921]. In these studies, the administration of T3 was associated with reduced infarct volume and a reduced neurologic deficit. The age association of T3 and prognosis after cerebral infarction in our study agrees with current knowledge regarding the physiologic changes in T3 levels and their regulation that occur with age. Serum total and free T3 levels have been found to be decreased [6, 7] in healthy older individuals. The same reduction in T3 with age was also found in our population. As for serum T4, some authors have found it to remain unchanged [69] whereas others have shown it to increase with age [10]. In our population, serum total and free T4 levels were demonstrated to be higher in older patients. These changes in thyroid-related hormone concentrations may be explained by a decrease in the peripheral conversion of T4 to T3, which may be due to the decrease activity of liver type I deiodinase with aging [6]. Therefore, compared with younger patients with similar T4 levels, older patients may have lower T3 concentrations, making the detrimental effect of lower T3 on disease prognosis more obvious.

On the other hand, it is well known that, within a few hours after the onset of stroke, plasma T3 decreases, and the magnitude of the change is related to the stroke severity [2225]. The association between lower T3 concentrations and greater stroke severity was confirmed in another recent meta-analysis [26]. Our study also showed the negative association between T3 (both total and free) concentrations and stroke severity in both age groups. Therefore, some authors believed the lower T3 levels found in stroke patients with the worse prognosis probably represent a marker of the severity of the disease [1]. However, the lower T3 and stroke severity association was reduced in older age [26], and our study found that the association between lower total T3 levels and poor outcome remained after adjusting for NIHSS scores, age and other variables associated with poor function on univariate analysis in patients at or above 65 years of age. In this context, our study has demonstrated that lower total T3 levels predict poor outcome after stroke beyond disease severity in older population.

Ischemic stroke increasing in incidence with age and tends to present with more severe symptoms; it also has worse outcomes in the elderly compared with younger patients [27]. As a special physiologic status, aging may also influence the prognostic value of some known or possible predictors of outcome after stroke (i.e., lower total T3 levels), as shown in this study. Therefore, it was appropriate to choose a population with variation in patients’ ages in order to study the prognostic value of candidate predictors. However, much remains to be learned about the association between the thyroid hormone profile and stroke outcome prior to considering the evaluation of serum T3 concentrations in the routine clinical setting for risk stratification and prognostication in patients with acute ischemic stroke.

Several limitations should be considered in the interpretation of our study. First, this is a retrospective study, which poses the risk of selection bias. Second, we lacked long-term clinical follow-up data on our patients. Third, we only use a mRS cut-off value to evaluate the functional outcome after stroke. One previous study has shown that reduced T3 concentrations can serve as an independent biomarker of worse cognitive outcomes after ischemic stroke, a common complication in stroke patients [28]. Further studies including more patient-centered outcomes are needed. Another limitation is that we lack the data about ischemic stroke etiology, which may be helpful to assigned obtained results to the stroke etiology. Finally, we had only a single baseline measurement and no dynamic monitoring of thyroid function. It has been reported that T3 values remain low until poststroke day 5 and then recover by days 7 to 9 after acute hemispheric stroke [29]. Future studies comprising the dynamic evaluation of thyroid function after stroke are desirable for validating the predictive role of thyroid hormone levels in acute stroke.

Conclusion

This study assessed the effect of age on the prognostic value of thyroid-related hormones in patients with acute ischemic stroke. We found that the prognostic value of lower total T3 for poor outcome after ischemic stroke may not always be confirmed in all age populations and that, instead, it may be more clinically meaningful in older patients. Therefore, selecting a population of the appropriate age in order to study the prognostic value of candidate predictors is reasonable.

Abbreviations

AUC: 

Area under the curve

CI: 

Confidence interval

CRP: 

C-reactive protein

IQR: 

Interquartile range

mRS: 

Modified Rankin Scale

NIHSS: 

National Institute of Health Stroke Scale

OR: 

Odds ratio

ROC: 

Receiver operating characteristics

SD: 

Standard deviation

T3: 

Triiodothyronine

T4: 

Thyroxine

TSH: 

Thyroid-stimulating hormone

WBC: 

White blood cell

Declarations

Acknowledgements

Not applicable.

Competing of interests

The authors declare that they have no competing interests.

Funding

This work was supported by Foundation of Zhejiang provincial science and Technology Department [No. 2016C34006] and Zhejiang Provincial Natural Science Foundation of China [No. LY17H090006].

Availability of data and materials

All data generated or analysed during this study are included in this published article.

Authors’ contributions

LQL designed the study and wrote the manuscript. XYX performed the analysis and interpretation of data as well as manuscript writing. WYL and XYH were responsible for the acquisition and interpretation of data and the manuscript revision. WL designed the study with LQL and made a critical revision for the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the ethic committee of the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. Patient’s consents were waived by the ethic committee of the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, due to the retrospective design of the study.

Consent for publication

Not applicable.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Intensive Care Unit, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, 310009, China
(2)
Department of Neurology, the Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, 310016, Hangzhou, China

References

  1. Alevizaki M, Synetou M, Xynos K, et al. Low triiodothyronine: a strong predictor of outcome in acute stroke patients. Eur J Clin Investig. 2007;37(8):651–7.View ArticleGoogle Scholar
  2. Ambrosius W, Kazmierski R, Gupta V, et al. Low free triiodothyronine levels are related to poor prognosis in acute ischemic stroke. Exp Clin Endocrinol Diabetes. 2011;119(3):139–43.View ArticleGoogle Scholar
  3. Zhang Y, Meyer MA. Clinical analysis on alteration of thyroid hormones in the serum of patients with acute ischemic stroke. Stroke Res Treat. 2010. https://doi.org/10.4061/2010/290678.
  4. Neidert S, Katan M, Schuetz P, et al. Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med. 2011;269(4):420–32.View ArticleGoogle Scholar
  5. Xu XY, Li WY, Hu XY. Alteration of thyroid-related hormones within normal ranges and early functional outcomes in patients with acute ischemic stroke. Int J Endocrinol. 2016. https://doi.org/10.1155/2016/3470490.
  6. van den Beld AW, Visser TJ, Feelders RA, et al. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005;90(12):6403–9.View ArticleGoogle Scholar
  7. Mariotti S, Franceschi C, Cossarizza A, et al. The aging thyroid. Endocr Rev. 1995;16(6):686–715.View ArticleGoogle Scholar
  8. Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab. 2012;97(5):1554–62.View ArticleGoogle Scholar
  9. Gesing A, Lewiński A, Karbownik-Lewińska M. The thyroid gland and the process of aging; what is new? Thyroid Res. 2012;5(1):16.View ArticleGoogle Scholar
  10. Waring AC, Arnold AM, Newman AB, et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab. 2012;97(11):3944–50.View ArticleGoogle Scholar
  11. Mingote E, Meroño T, Rujelman R, et al. High TSH and low T4 as prognostic markers in older patients. Hormones (Athens). 2012;11(3):350–5.View ArticleGoogle Scholar
  12. Fries BE, Morris JN, Skarupski KA, et al. Accelerated dysfunction among the very oldest-old in nursing homes. J Gerontol A Biol Sci Med Sci. 2000;55(6):M336–41.View ArticleGoogle Scholar
  13. American College of Emergency Physicians, American Geriatrics Society, Emergency Nurses Association, Society for Academic Emergency Medicine, Geriatric Emergency Department Guidelines Task Force. Geriatric emergency department guidelines. Ann Emerg Med. 2014;63(5):e7–25.View ArticleGoogle Scholar
  14. Dayan CM. Interpretation of thyroid function tests. Lancet. 2001;357(9256):619–24.View ArticleGoogle Scholar
  15. Bunevicius A, Iervasi G, Bunevicius R. Neuroprotective actions of thyroid hormones and low-T3 syndrome as a biomarker in acute cerebrovascular disorders. Expert Rev Neurother. 2015;15(3):315–26.View ArticleGoogle Scholar
  16. Wang Y, Zhou S, Bao J, et al. Low T3 levels as a predictor marker predict the prognosis of patients with acute ischemic stroke. Int J Neurosci. 2017;127(7):559–66.View ArticleGoogle Scholar
  17. Suda S, Muraga K, Kanamaru T, et al. Low free triiodothyronine predicts poor functional outcome after acute ischemic stroke. J Neurol Sci. 2016;368:89–93.View ArticleGoogle Scholar
  18. Jiang X, Xing H, Wu J, et al. Prognostic value of thyroid hormones in acute ischemic stroke - a meta analysis. Sci Rep. 2017;7(1):16256.View ArticleGoogle Scholar
  19. Hiroi Y, Kim HH, Ying H, et al. Rapid nongenomic actions of thyroid hormone. Proc Nati Acad Sci U S A. 2006;103(38):14104–9.View ArticleGoogle Scholar
  20. Mdzinarishvili A, Sutariya V, Talasila PK, et al. Engineering triiodothyronine (T3) nanoparticle for use in ischemic brain stroke. Drug Deliv Transl Res. 2013;3(4):309–17.View ArticleGoogle Scholar
  21. Sayre NL, Sifuentes M, Holstein D, et al. Stimulation of astrocyte fatty acid oxidation by thyroid hormone is protective against ischemic stroke-induced damage. J Cereb Blood Flow Metab. 2017;37(2):514–27.View ArticleGoogle Scholar
  22. Wartofsky L, Burman KD. Alterations in thyroid function in patients with systemic illness: the “euthyroid sick syndrome”. Endocr Rev. 1982;3(2):164–217.View ArticleGoogle Scholar
  23. Bianco AC, Salvatore D, Gereben B, et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23(1):38–89.View ArticleGoogle Scholar
  24. Docter R, Krenning EP, de Jong M, et al. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol. 1993;39(5):499–518.View ArticleGoogle Scholar
  25. Rothwell PM, Lawler PG. Prediction of outcome in intensive care patients using endocrine parameters. Crit Care Med. 1995;23(1):78–83.View ArticleGoogle Scholar
  26. Lamba N, Liu C, Zaidi H, et al. A prognostic role for low tri-iodothyronine syndrome in acute stroke patients: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;169:55–63.View ArticleGoogle Scholar
  27. Hilditch CA, Nicholson P, Murad MH, et al. Endovascular Management of Acute Stroke in the elderly: a systematic review and Meta-analysis. AJNR Am J Neuroradiol. 2018;39(5):887–91.View ArticleGoogle Scholar
  28. Bunevicius A, Kazlauskas H, Raskauskiene N, et al. Ischemic stroke functional outcomes are independently associated with C-reactive protein concentrations and cognitive outcomes with triiodothyronine concentrations: a pilot study. Endocrine. 2014;45(2):213–20.View ArticleGoogle Scholar
  29. Schwarz S, Schwab S, Klinga K, et al. Neuroendocrine changes in patients with acute space occupying ischaemic stroke. J Neurol Neurosurg Psychiatry. 2003;74(6):725–7.View ArticleGoogle Scholar

Copyright

© The Author(s). 2019

Advertisement